Financials data is unavailable for this security.
View more
Year on year Pfizer Inc 's revenues fell -41.70% from 100.33bn to 58.50bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 31.37bn to 2.12bn, a -93.25% decrease.
| Gross margin | 70.45% |
|---|---|
| Net profit margin | -0.46% |
| Operating margin | -6.04% |
| Return on assets | -0.12% |
|---|---|
| Return on equity | -0.30% |
| Return on investment | -0.15% |
More ▼
Cash flow in USDView more
In 2023, Pfizer Inc increased its cash reserves by 523.29%, or 2.45bn. Cash Flow from Financing totalled 26.07bn or 44.56% of revenues. In addition the company generated 8.70bn in cash from operations while cash used for investing totalled 32.28bn.
| Cash flow per share | 1.11 |
|---|---|
| Price/Cash flow per share | 25.62 |
| Book value per share | 16.28 |
|---|---|
| Tangible book value per share | -7.03 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.05 |
|---|---|
| Quick ratio | 0.7784 |
| Total debt/total equity | 0.7536 |
|---|---|
| Total debt/total capital | 0.429 |
More ▼
Growth rates in USD
Growth rate information is not available.
| Div yield(5 year avg) | 3.85% |
|---|---|
| Div growth rate (5 year) | 3.82% |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -7.10 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -101.20 |
More ▼
